I forbindelse med brug af cerivastatin kombineret med fibrater (primært gemfibrozil) steg indberetningsfrekvensen betydeligt ved stigende doser alt efter indberetningsregionen.
When cerivastatin was used concomitantly with fibrates (primarily gemfibrozil), there was a substantially higher reporting rate with increasing dose, depending on the reporting region.